Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Market Commentary

Tech Stocks Retreat as Powell’s Caution Tempers Rally

Dieter Jaworski by Dieter Jaworski
September 24, 2025
in Market Commentary, Nasdaq, Tech & Software
0
NASDAQ 100 Stock
0
SHARES
122
VIEWS
Share on FacebookShare on Twitter

The Nasdaq 100 snapped its record-breaking run on Thursday, closing lower after cautious commentary from Federal Reserve Chair Jerome Powell prompted a wave of profit-taking. The technology-heavy index finished the session down 178.94 points, or 0.73%, settling at 24,580.17.

Market Reversal Follows Early Gains

Trading began on a positive note, with the index climbing to an intraday peak of 24,764.30 points shortly after the opening bell. However, the mood shifted decisively following Powell’s remarks. The Fed Chairman jolted investors by stating that equities appear “fairly highly priced” and cautioning that there is “no risk-free path” for monetary policy.

This sentiment triggered a sell-off, dragging the Nasdaq 100 to a daily low of 24,536.50. A modest recovery in the final hour of trading pared some of the session’s losses.

Should investors sell immediately? Or is it worth buying NASDAQ 100?

Broader Market Weakness and Rising Uncertainty

The pullback was not isolated to the tech sector. Broader U.S. equity indices also faced pressure, reflecting a market-wide increase in caution. The S&P 500 declined by 0.6%, while the Dow Jones Industrial Average dipped 0.2%. The growing unease was further evidenced by a rise in the CBOE Volatility Index (VIX), a key gauge of market fear.

The question now facing investors is whether this marks a temporary pause for the market’s leading technology shares or the beginning of a more significant correction. The sustainability of the recent rally will be tested in the coming trading sessions.

Ad

NASDAQ 100 Stock: Buy or Sell?! New NASDAQ 100 Analysis from February 8 delivers the answer:

The latest NASDAQ 100 figures speak for themselves: Urgent action needed for NASDAQ 100 investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

NASDAQ 100: Buy or sell? Read more here...

Tags: NASDAQ 100
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
NextDecade Stock

A Tale of Two Perspectives: NextDecade's Conflicting Signals

HCA Healthcare Stock

HCA Healthcare: Balancing Shareholder Returns with Strategic Growth Initiatives

Sasol Stock

Sasol Shares Face Analyst Scrutiny Amid Cash Flow Concerns

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com